Immune Checkpoint Inhibitors Current Advances and Future Perspective

Authors

  • Zhijun Jiang
  • Yuhang Liu
  • Haohui Wang

DOI:

https://doi.org/10.54097/ykhjgh37

Keywords:

Immune checkpoint, immune therapy, CTLA-4, PD-1, PD-L1.

Abstract

Immune therapy has become the fourth method to treat tumors after the traditional methods including radiotherapy, chemotherapy and surgery. Immune therapies use humans’ innate immune system to fight against tumors. Nowadays there are many immune therapies used in clinic, including immune checkpoint inhibitors, cancer vaccines, cytokine therapies, and so on. One of the most mature and widely used immune therapies is immune checkpoint inhibitors (ICIs). Because tumor surface have some proteins that can bind to the receptors on the immune cells, once they are bound the function of the immune system will be inhibited and so tumors can live in human bodies and not be killed by the immune system. Immune checkpoint inhibitor is a method that uses different proteins to block the receptors on the immune cells and the ligands on the tumor cells. In that way, the immune cells will be activated, and kill the tumors. It is worth mentioning that immune checkpoint inhibitors CTLA-4 and PD-1 have made some process in clinical. This article will review some immune checkpoints, make detailed introductions about immune checkpoints CTLA-4, PD-1, and PD-L1 and their recent advances and some immune checkpoints under investigation.

Downloads

Download data is not yet available.

References

Zeng Zhu, Liao Zhengyin. Application of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma [J]. West China Medicine, 2020,35(2):6.

Ma Mingquan, Tang Peng. New progress in the clinical research of PD-1 inhibitors in the treatment of esophageal cancer [J]. Chinese Oncology Clinical, 2021,48(18):6.

Jhaveri K D , Wanchoo R .Adverse Events Associated With Immune Checkpoint Inhibitors[J].JAMA, 2019, 321(12).

Venditti, O., De Lisi, D., Caricato, M. et al. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer 15, 87 (2015).

Ribas, A. (2007). Anti-CTLA4 antibody clinical trials in melanoma. Update on Cancer Therapeutics, 2(3), 133–139.

Abedi Kiasari, B., Abbasi, A., Ghasemi Darestani, N., Adabi, N., Moradian, A., Yazdani, Y., Sadat Hosseini, G., Gholami, N., & Janati, S. (2022). Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology,113,109365

Sidaway, P. Anti-PD-L1 therapy: patient selection is important. Nat Rev Clin Oncol 13, 134 (2016).

Liang, Y., Tang, H., Guo, J. et al. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat Commun 9, 4586 (2018).

Chen, TC., Chen, CH., Wang, CP. et al. The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment. Sci Rep 7, 10349 (2017).

Graydon CG, Mohideen S, Fowke KR. LAG3's Enigmatic Mechanism of Action. Front Immunol. 2021 Jan 8;11:615317.

Xu Biobo, He Yijing, Wang Weili, et al. Progress in the clinical treatment of tumor immune checkpoint inhibitors [J]. Clinical Pharmacology and Therapeutics in China, 2016,21 (2): 7.

Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022 Jul 26;13:956090.

Downloads

Published

29-12-2023